行情

CYCC

CYCC

赛拉喜
NASDAQ

实时行情|Nasdaq Last Sale

3.320
-0.220
-6.21%
盘后: 3.320 0 0.00% 16:00 01/19 EST
开盘
3.460
昨收
3.540
最高
3.510
最低
3.300
成交量
5.65万
成交额
--
52周最高
11.42
52周最低
3.150
市值
3,311.74万
市盈率(TTM)
-0.9708
分时
5日
1月
3月
1年
5年
Cyclacel Pharmaceuticals reveals plans for cancer drug programs for 2022
Cyclacel Pharmaceuticals (NASDAQ:CYCC) announced business objectives for 2022. The company expects to dose first patient in its third phase 1/2 study evaluating CYC140 across various solid tumors. Cyclacel is also planning
Seekingalpha · 01/06 13:29
BRIEF-Cyclacel Pharmaceuticals Announces Key Business Objectives For 2022
reuters.com · 01/06 12:42
Low-Volume Stock Cyclacel Shares Tick Higher Following National Institutes Of Health ClinicalTrials.gov Listing For Co.'s 'Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome,' Shows Recruiting
https://clinicaltrials.gov/ct2/show/NCT05168904
Benzinga · 2021/12/23 15:35
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced t...
GlobeNewswire · 2021/12/23 12:00
Vow ASA: Vow strengthens partnership with Respol with agreement to deliver pilot plant using ETIA pyrolysis technology
Vow ASA's (VOW) subsidiary ETIA has received the confirmation from Repsol to deliver a pilot plant to demonstrate the capabilities of VOW Biogreen® systems integration in petrochemical and refineries sites for processing alternative feedstock to generate f...
GlobeNewswire · 2021/12/20 07:00
Vow ASA: Vow bags USD 5.2 million cruise retrofit contract
Vow ASA (“Vow”) has through its subsidiary Scanship been awarded a USD 5.2 million retrofit contract with one of the major cruise line companies. Scanship has entered a USD 5.2 million turnkey contract for the supply and installation of its advanced wastew...
GlobeNewswire · 2021/12/07 10:25
Tri Locum Partners LP Buys Baxter International Inc, Seagen Inc, Merck Inc, Sells Regeneron ...
GuruFocus News · 2021/11/16 13:38
BRIEF-Cyclacel Pharma Reports Q3 2021 Financial Results
reuters.com · 2021/11/10 22:35
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CYCC最新的财务预测,通过CYCC每股收益,每股净资产,每股现金流等数据分析赛拉喜近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

50.00%强力推荐
50.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CYCC价格均价为20.00,最高价位24.00,最低价为17.00。
最高24.00
均价20.00
最低17.00
现价3.320
EPS
实际EPS
预期EPS
-1.07-0.80-0.54-0.27
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 34
机构持股: 372.34万
持股比例: 37.33%
总股本: 997.51万
类型机构数股数
增持
8
49.13万
建仓
5
5.92万
减持
9
48.42万
平仓
5
45.97万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.06%
制药与医学研究
-0.76%
高管信息
Non-Executive Chairman/Independent Director
Christopher Henney
President/Chief Executive Officer/Director
Spiro Rombotis
Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director
Paul Mcbarron
Senior Vice President
Mark Kirschbaum
Independent Director
Samuel Barker
Independent Director
Gregory Hradsky
Independent Director
Brian Schwartz
Independent Director
Lloyd Sems
Independent Director
Robert Spiegel
Independent Director
Karin Walker
公告日期
每股分红
除权日期
2016/05/26
每股分红:USD 0.15
2016/07/13
CYCC 简况
Cyclacel Pharmaceuticals, Inc.在细胞周期生物学领域开展业务。该公司生产多种作用于细胞周期的抗癌药物,包括核苷类似物、周期蛋白依赖性激酶(CDK)抑制剂、polo样激酶(PLK)抑制剂和极光激酶/血管内皮生长因子受体(AK/VEGFR)抑制剂。该公司作用于细胞周期的抗癌药物包括sapacitabine、seliciclib和CYC065。该公司的主要候选产品sapacitabine是一种口服核苷类似物。一系列核苷类药物(如吉西他滨和阿糖胞苷(也称为Ara-C))均为被用作传统化学疗法的通用名药物。该公司的主导CDK抑制剂seliciclib是CDK2/9酶的口服抑制剂,对细胞分裂与细胞周期控制的过程至关重要。该公司的第二代CDK抑制剂CYC065是一种靶向CDK2/9酶的抑制剂,用于治疗血液恶性肿瘤和实体瘤。

微牛提供Cyclacel Pharmaceuticals Inc(NASDAQ-CYCC)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CYCC股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CYCC股票基本功能。